货号:A238238
同义名:
NSC 125973; PTX
Paclitaxel 是一种天然抗肿瘤药物,能稳定微管蛋白 (tubulin) 的聚合,导致有丝分裂停滞和诱导细胞凋亡 (apoptosis),最终导致细胞死亡。Paclitaxel 还可诱导细胞自噬 (autophagy)。Paclitaxel通过微管聚合抑制体外神经突的启动和生长。
HazMat Fee + There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.
| Type | HazMat fee for 500 gram (Estimated) |
| Excepted Quantity | USD 0.00 |
| Limited Quantity | USD 15-60 |
| Inaccessible (Haz class 6.1), Domestic | USD 80+ |
| Inaccessible (Haz class 6.1), International | USD 150+ |
| Accessible (Haz class 3, 4, 5 or 8), Domestic | USD 100+ |
| Accessible (Haz class 3, 4, 5 or 8), International | USD 200+ |


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 产品名称 | Autophagy ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SBI-0206965 |
+++
ULK1, IC50: 108 nM ULK2, IC50: 711 nM |
95% | |||||||||||||||||
| Hydroxychloroquine sulfate | ✔ | 99% | |||||||||||||||||
| Valproic acid sodium | ✔ | HDAC | 97% | ||||||||||||||||
| PFK-015 |
++
PFKFB3, IC50: 207 nM |
99%+ | |||||||||||||||||
| MRT68921 HCl |
++++
ULK1, IC50: 2.9 nM ULK2, IC50: 1.1 nM |
99%+ | |||||||||||||||||
| ROC-325 | ✔ | 99%+ | |||||||||||||||||
| Autophinib |
+++
Autophagy, IC50: 40 nM |
99% | |||||||||||||||||
| Lys05 | ✔ | 99%+ | |||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 描述 | Microtubules are the main constituent of mitotic apparatus in all eukaryotic cells, thus make it become an important pharmacological target for the treatment of tumor[1]. Paclitaxel can stabilize the microtubule formation through interacting with β-tubulin[2] and then promoting the polymerization and assembly of it[3]. Paclitaxel show the inhibitory effect on HMVEC proliferation with IC50 of 0.1 pM, much lower than the IC50 of 5-FU, camptothecin, cisplatin and doxorubicin[4]. Paclitaxel induces G2/M arrest of cell cycle, thus it also used in synchronization in cell cycle[5]. Paclitaxel was approved by FDA in treatment of ovarian cancer, breast cancer, non-small-cell lung cancer[6], etc.. |
| 作用机制 | Paclitaxel can stabilize the microtubule formation through interacting with β-tubulin[2] and then promoting the polymerization and assembly of it[3]. |
| Concentration | Treated Time | Description | References | |
| HCT15 cells | 50 µg/ml | 24 hours | To compare the apoptosis-inducing effects of UTD1 and paclitaxel in ABCB1 high-expression cells, UTD1 showed stronger apoptosis-inducing ability | Cell Death Dis. 2021 Apr 1;12(4):338. |
| KPC tumor cells | 10μM | 36 hours | To evaluate the effect of paclitaxel on Cytidine deaminase protein levels, results showed paclitaxel reduced Cda protein levels through ROS-mediated degradation | Cancer Discov. 2012 Mar;2(3):260-269. |
| BxPC3 cells | 3-50 μg/ml | 48 h | To evaluate the drug delivery efficacy of PEI-MSNP in BxPC3 cells, results showed that PEI-MSNP effectively delivered Paclitaxel, leading to increased cytotoxicity. | ACS Nano. 2009 Oct 27;3(10):3273-86. |
| PANC-1 cells | 3-50 μg/ml | 48 h | To evaluate the drug delivery efficacy of PEI-MSNP in PANC-1 cells, results showed that PEI-MSNP effectively delivered Paclitaxel, leading to increased cytotoxicity. | ACS Nano. 2009 Oct 27;3(10):3273-86. |
| H460 cells | 5 μM | 48 h | To evaluate the cytotoxicity of PTX/TPGS nanocrystals on H460 cells, results showed significant inhibition of H460 cell proliferation. | Mol Pharm. 2010 Jun 7;7(3):863-9. |
| KB cells | 5 μM | 48 h | To evaluate the cytotoxicity of PTX/TPGS nanocrystals on KB cells, results showed significant inhibition of KB cell proliferation. | Mol Pharm. 2010 Jun 7;7(3):863-9. |
| NCI/ADR-RES cells | 5 μM | 48 h | To evaluate the cytotoxicity of PTX/TPGS nanocrystals on drug-resistant cancer cells, results showed significant inhibition of NCI/ADR-RES cell proliferation. | Mol Pharm. 2010 Jun 7;7(3):863-9. |
| 4T1 cells with M2 macrophages derived from RAW264.7 cells | 2.5 μM + 2.5 μM | 14 days | The combination of IPI-549 and paclitaxel (PTX) completely inhibited the growth of 3D multicellular tumor spheroids (MTCs), while IPI-549 or PTX alone showed limited inhibition. | Sci Transl Med. 2022 May 4;14(643):eabl3649. |
| Bone marrow-derived macrophages (BMDMs) | 5 μM | The combination of IPI-549 with paclitaxel (PTX) enhanced the repolarization of M2 macrophages to M1 macrophages, as indicated by an increase in M1 markers (TNF-α and IL-12) and a decrease in M2 markers (IL-10 and TGF-β). | Sci Transl Med. 2022 May 4;14(643):eabl3649. | |
| A549 cells | 10 –80 ng/mL | 48 h | To investigate the effect of Paclitaxel on CTSL expression in A549 cells, results showed that Paclitaxel treatment induced CTSL expression. | Acta Pharmacol Sin. 2016 Dec;37(12):1606-1622. |
| Administration | Dosage | Frequency | Description | References | ||
| Mice | Chemotherapy-induced bile acid metabolism disorder model | Intraperitoneal injection | 30 mg/kg | Every other day, total six doses | To investigate the effect of chemotherapy on bile acid metabolism, results showed chemotherapy reduced the level of secondary bile acid HDCA | Gut Microbes. 2024 Jan-Dec;16(1):2410475 |
| Nude mice | NCI/ADR-RES xenograft model | Intravenous injection | 10 mg/kg | Administered on days 0, 3, 6, 9, 12 | To evaluate the antitumor efficacy of PTX/TPGS nanocrystals in the NCI/ADR-RES xenograft model, results showed significant tumor growth inhibition. | Mol Pharm. 2010 Jun 7;7(3):863-9. |
| Mice | MDA-MB-231 xenograft | Oral ceritinib + Intraperitoneal paclitaxel | 10 mg/kg | Ceritinib once daily for 2 weeks; paclitaxel twice weekly for 2 weeks | To evaluate the inhibitory effect of ceritinib and paclitaxel combination therapy on ARlow TNBC tumor growth. Results showed that the combination treatment significantly inhibited tumor growth and lung metastasis. | Mol Cancer. 2022 Jun 29;21(1):138. |
| Mice | MMTV-PyMT transgenic mice with spontaneous breast cancer and lung metastasis | Intravenous injection | 10 mg/kg | Once every 3 days for five doses | The combination of Nano-PI with α-PD1 achieved long-term tumor remission, eliminated lung metastasis, and significantly improved survival in MMTV-PyMT transgenic mice. | Sci Transl Med. 2022 May 4;14(643):eabl3649. |
| Mice | Cognitive impairment model | Intraperitoneal injection | 20 mg/kg | Every other day for 4 doses | To investigate the mechanism of paclitaxel-induced cognitive impairment and evaluate the therapeutic effects of lithium and PKC inhibitors. Results showed that paclitaxel injections impaired short-term spatial memory in mice, altered neuronal morphology in the hippocampus and prefrontal cortex, and upregulated PKCα expression. Pretreatment with lithium and PKC inhibitors rescued these deficits. | Mol Neurodegener. 2021 Jun 26;16(1):41 |
| BALB/c nude mice | A549 cell xenograft model | Intraperitoneal injection | 10 mg/kg, 15 mg/kg | Every 3 days for 2 weeks | To investigate the effect of Paclitaxel on A549 cells overexpressing CTSL in a xenograft model, results showed that overexpression of CTSL reduced sensitivity to Paclitaxel. | Acta Pharmacol Sin. 2016 Dec;37(12):1606-1622. |
| Dose | Mice: min = 2 mg/kg[7] (i.v.), max = 75 mg/kg[8] (i.p.) | ||||||||||||||||||||
| Administration | i.v., i.p. | ||||||||||||||||||||
| Pharmacokinetics |
|
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
1.17mL 0.23mL 0.12mL |
5.86mL 1.17mL 0.59mL |
11.71mL 2.34mL 1.17mL |
|
| CAS号 | 33069-62-4 |
| 分子式 | C47H51NO14 |
| 分子量 | 853.91 |
| SMILES Code | O=C1[C@H](OC(C)=O)C(C2(C)C)=C(C)[C@@H](OC([C@H](O)[C@@H](NC(C3=CC=CC=C3)=O)C4=CC=CC=C4)=O)C[C@@]2(O)[C@@H](OC(C5=CC=CC=C5)=O)[C@@]6([H])[C@@]1(C)[C@@H](O)C[C@@]7([H])OC[C@]76OC(C)=O |
| MDL No. | MFCD00869953 |
| 别名 | NSC 125973; PTX |
| 运输 | 蓝冰 |
| InChI Key | RCINICONZNJXQF-MZXODVADSA-N |
| Pubchem ID | 36314 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry, store in freezer, under -20°C |
| 溶解方案 |
DMSO: 105 mg/mL(122.96 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1